how were glp 1 drugs discovered Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions GLP-1 medications get at the

In conclusion, GLP-1R plays important roles in mitochondrial dysfunction and OS in AD and DM

Perhaps the biggest splash to the GLP-RA pool has come with the PIONEER trials for oral semaglutide

As for clinical outcomes, in the T2DM group, there was a significant reduction in HbA1c (decreased by 1.01% to 1.02%, placebo-adjusted) and a clinically meaningful decrease in body weight of 3.26% to 3.51% after 12 weeks of treatment

4 The burden of MASLD is projected to increase exponentially, with anticipated rises of 21% and 63% in cases of MASLD and MASH, respectively

Our results are generally consistent in direction and magnitude with the existing clinical research, including trials showing reduced heavy alcohol consumption among those with obesity,14 reduced drinking in an experimental bar setting,12 and pharmacoepidemiological analyses showing that GLP-1 receptor agonists are associated with lower incidence and recurrence of alcohol use disorder,2 reduced need for tobacco use related care,5 lower incidence and relapse of cannabis use disorder,4 and reduced risk of opioid overdose in patients with opioid use disorders.8 Our results show that among people with a pre-existing SUD, GLP-1 receptor agonist use was associated with a reduced risk of several adverse clinical outcomes (SUD related emergency department visits, hospital admission, and mortality, drug overdose, and suicidal attempt or ideation)

E., and Schweizer A., Improved MealRelated Insulin Processing Contributes to the Enhancement of BCell Function by the DPP4 Inhibitor Vildagliptin in Patients With Type 2 Diabetes, Hormone and Metabolic Research 39, no